Furthermore, IGF1-driven IGF1R activation promotes tumor progression both in vitro and in vivo, while IGF1R inhibition via linsitinib effectively reduces these oncogenic effects, highlighting the significance of the PTPN9–IGF1R signaling axis in cholangiocarcinoma. Here, IGF1R is linked to cholangiocarcinoma.